ReviewProstate cancer and prostatic diseases2020
Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI.
Review in Prostate cancer and prostatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06929065 (Randomized Prospective Trial of Focal Therapy), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Prospective Trial of Focal Therapy (HIFU vs Cryo) for Early Stage Unifocal Prostate Cancer
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- MRI after focal therapy for prostate cancer: what radiologists must know?Abdominal radiology (New York) · 2025Review
- Focal therapy of prostate cancer: Use of artificial intelligence to define tumour volume and predict treatment outcomes.BJUI compass · 2025Article
- Artificial Intelligence Improves the Ability of Physicians to Identify Prostate Cancer Extent.The Journal of urology · 2024Article
- Clinical efficacy of prostate PI-RADS V2.1 score combined with serum PSA-related indicators in the detection of gray zone prostate cancer.International urology and nephrology · 2023Article
- Real-Time and Delayed Imaging of Tissue and Effects of Prostate Tissue Ablation.Current urology reports · 2023Review
- Prediction and Mapping of Intraprostatic Tumor Extent with Artificial Intelligence.European urology open science · 2023Article
- Landmarks in the evolution of prostate biopsy.Nature reviews. Urology · 2023Review
- Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review.Frontiers in oncology · 2023Review
- Safety and Feasibility of Transperineal Targeted Microwave Ablation for Low- to Intermediate-risk Prostate Cancer.European urology open science · 2022Article
- Article
- Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors.Diagnostics (Basel, Switzerland) · 2022Review
- High-Intensity Focused-Ultrasound Focal Therapy Versus Laparoscopic Radical Prostatectomy: A Comparison of Oncological and Functional Outcomes in Low- and Intermediate-Risk Prostate Cancer Patients.Journal of personalized medicine · 2022Article
- Machine Learning in Prostate MRI for Prostate Cancer: Current Status and Future Opportunities.Diagnostics (Basel, Switzerland) · 2022Review
- Oncological and functional outcome after partial prostate HIFU ablation with Focal-OneProstate cancer and prostatic diseases · 2021Article
- Focal therapy for primary and salvage prostate cancer treatment: a narrative review.Translational andrology and urology · 2021Review
- MR-Guided High-Intensity Directional Ultrasound Ablation of Prostate Cancer.Current urology reports · 2021Review
- Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment.International journal of nanomedicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundProstate cancer focal therapy aims to minimize the side-effects of whole gland treatments, such as radical prostatectomy and radiotherapy without compromising oncological efficacy. However, concerns exist regarding the multifocal nature of prostate cancer and the lack of long-term oncological data for this form of treatment. In recent years, the routine adoption of multi-parametric magnetic resonance imaging (mpMRI) of the prostate has improved our ability to select candidates for focal therapy and to accurately deliver this form of prostate cancer treatment.
methodsWe performed a review of the literature to provide a summary of the oncological and functional outcomes of men receiving primary prostate focal therapy. Furthermore, we discuss the impact of the routine implementation of mpMRI as part of the initial prostate cancer diagnostic pathway on the selection of candidates and delivery of focal therapy. Finally, we summarize knowledge gaps in the field and highlight active clinical trials in this arena.
resultsPrimary focal therapy involves the application of one of a number of energies that ablate tissue, such as cryotherapy and high intensity focused ultrasound (HIFU). Success is principally dependent on highly accurate patient selection and disease localization underpinned in large part by the routine integration of pre-biopsy mpMRI. Prospective medium-term follow-up data for primary HIFU and cryotherapy for men with intermediate-risk disease have shown acceptable cancer control with low risk of side effects and complications. Additional research is needed to clearly define an appropriate follow-up approach and to guide the management of in- and out-of-field recurrences. Multiple comparative trials with randomization against standard care are currently underway in men with intermediate- and high-risk prostate cancer.
conclusionThe widespread adoption of prostate mpMRI has led to improved disease localization, enabling the performance of focal therapy as a viable treatment strategy for men with low volume intermediate-risk prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.